A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis

<div>Forest plot of (a) ORR, (b) OS, and (c) PFS in NSCLC patients treated with platinum-based chemotherapy in relation to ERCC1 C118T polymorphism (CT + TT versus CC).</div>

Disease Markers

fig2

Figure 2

Figure 2: A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis 

Figure 2 | A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis 